DCT

1:26-cv-01010

Novartis Pharma Corp v. Cipla USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-01010, D. Del., 08/10/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant Cipla USA Inc. is a Delaware corporation, and Defendant Cipla Ltd. is subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiffs' LEQVIO® (inclisiran) product constitutes an act of infringement of two patents related to RNA interference (RNAi) technology for inhibiting PCSK9 gene expression.
  • Technical Context: The technology involves using small interfering RNA (siRNA) to reduce the expression of the PCSK9 gene, a key regulator of cholesterol metabolism, as a treatment for hypercholesterolemia.
  • Key Procedural History: The complaint notes that a prior lawsuit was filed on March 13, 2026, by the same Plaintiffs against Cipla concerning the same patents-in-suit and an additional patent, U.S. Patent No. 12,460,206. That action is identified as Novartis Pharmaceutical Corp. v. Cipla USA Inc., C.A. 26-272-GBW (D. Del.).

Case Timeline

Date Event
2013-10-04 '369 Patent Priority Date
2015-08-25 '377 Patent Priority Date
2018-11-13 '369 Patent Issue Date
2020-12-01 '377 Patent Issue Date
2026-01-28 Cipla sends prior notice letter regarding Patents-in-Suit
2026-03-13 Plaintiffs file prior complaint against Cipla (C.A. 26-272-GBW)
2026-06-26 Cipla sends notice letter for the current action
2026-08-10 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,125,369 - PCSK9 iRNA compositions and methods of use thereof

  • Patent Identification: U.S. Patent No. 10,125,369, issued November 13, 2018.

The Invention Explained

  • Problem Addressed: The patent's background section identifies that long-standing elevation of serum cholesterol can lead to atherosclerosis and related cardiovascular events like myocardial infarction and stroke '369 Patent, col. 1:20-29 It links the protein PCSK9 to the regulation of cholesterol levels '369 Patent, col. 2:1-4
  • The Patented Solution: The invention is a double-stranded RNA interference (RNAi) agent designed to inhibit the expression of the PCSK9 gene '369 Patent, abstract '369 Patent, col. 2:41-45 The agent comprises a sense strand and an antisense strand with specific chemical modifications and is conjugated to a ligand, such as a GalNAc derivative, to facilitate targeted delivery, particularly to the liver '369 Patent, col. 4:41-44
  • Technical Importance: The invention provides a composition of matter for a therapeutic that uses RNA interference to silence a key gene involved in cholesterol metabolism, employing a ligand-conjugated design to improve drug delivery and efficacy.

Key Claims at a Glance

  • The complaint identifies claim 52 as an exemplary infringed claim, which is dependent on claim 1 Compl. ¶37 Compl. ¶45 The complaint also states that infringement of claims 1-52, 54-63, and 65-85 was not contested on any basis other than invalidity Compl. ¶40 Independent claim 1 is analyzed:
    • A double stranded RNAi agent that inhibits the expression of Proprotein convertase subtilisin kexin 9 (PCSK9) in a cell;
    • comprising a sense strand complementary to an antisense strand forming a double stranded region, wherein said antisense strand comprises at least 19 contiguous nucleotides of the nucleotide sequence 5'-ACAAAAGCAAAACAGGUCUAG-3' (SEQ ID NO: 412);
    • and said double stranded RNAi agent is represented by formula (III);
    • wherein the sense strand is conjugated to at least one ligand which is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.
  • The complaint alleges infringement of "one or more claims" and reserves the right to assert other claims Compl. ¶37

U.S. Patent No. 10,851,377 - Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

  • Patent Identification: U.S. Patent No. 10,851,377, issued December 1, 2020.

The Invention Explained

  • Problem Addressed: The patent addresses the need for methods to treat disorders associated with the PCSK9 gene, such as hyperlipidemia and hypercholesterolemia '377 Patent, col. 1:47-53
  • The Patented Solution: The invention is a method for inhibiting PCSK9 expression by administering a specific "fixed dose" of a double-stranded RNAi agent '377 Patent, abstract The patent claims a method comprising the subcutaneous administration of a fixed dose between 275 mg and 325 mg of a specifically defined RNAi agent conjugated to a GalNAc ligand '377 Patent, claim 1
  • Technical Importance: This patent protects a specific therapeutic regimen for the RNAi composition, covering a defined fixed dosage range, a critical aspect of protecting a commercially approved drug product's method of use.

Key Claims at a Glance

  • The complaint identifies claim 1 as an exemplary infringed claim Compl. ¶60 Compl. ¶69 The complaint also notes that infringement of claims 1-30 was not contested on any basis other than invalidity Compl. ¶64 Independent claim 1 is analyzed:
    • A method of inhibiting the expression of a... PCSK9 gene in a human subject;
    • comprising subcutaneously administering to the subject a fixed dose of 275 mg to 325 mg of a double stranded ribonucleic acid (RNAi) agent, or salt thereof;
    • wherein the double stranded RNAi agent comprises a sense strand and an antisense strand with specific, recited nucleotide sequences (SEQ ID NO: 687 and SEQ ID NO: 688, respectively);
    • and wherein the double stranded RNAi agent is conjugated to a N-acetylgalactosamine (GalNAc)3 ligand.
  • The complaint alleges infringement of "one or more claims" and reserves the right to assert other claims Compl. ¶60

III. The Accused Instrumentality

Product Identification

  • Cipla's ANDA Product, identified as a generic version of LEQVIO® (inclisiran) injection, 284 mg/1.5 mL Compl. ¶1 Compl. ¶27

Functionality and Market Context

  • The complaint alleges that the accused product contains inclisiran, which is described as a double-stranded RNAi agent designed to inhibit the expression of PCSK9 in a cell Compl. ¶38 Compl. ¶62 The product is intended for the same therapeutic indications as LEQVIO®, which is used as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia Compl. ¶26 The complaint alleges that Cipla's ANDA Product is not a staple article of commerce and is not suitable for substantial noninfringing use Compl. ¶43 Compl. ¶67

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

  • '369 Patent Infringement Allegations
Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A double stranded RNAi agent that inhibits the expression of Proprotein convertase subtilisin kexin 9 (PCSK9) in a cell... The accused product contains inclisiran, which is alleged to be "a double stranded RNAi agent that inhibits the expression of PCSK9 in a cell." ¶38 col. 2:41-45
...comprising a sense strand complementary to an antisense strand forming a double stranded region... The accused product's active ingredient, inclisiran, is alleged to comprise a sense strand and an antisense strand. ¶39 col. 2:46-49
...wherein said antisense strand comprises at least 19 contiguous nucleotides of the nucleotide sequence 5'-ACAAAAGCAAAACAGGUCUAG-3' (SEQ ID NO: 412)... The accused product's inclisiran is alleged to contain an antisense strand with the nucleotide sequence 5′-asCfsaAfAfAfgCfaAfaAfcAfgGfuCfuagsasa-3′ (SEQ ID NO:1663), which is alleged to meet this limitation. ¶39 col. 751:49-51
...and said double stranded RNAi agent is represented by formula (III)... Inclisiran is alleged to contain specific 2'-O-methyl, 2'-fluoro, and phosphorothioate chemical modifications that are alleged to fall within the scope of formula (III). ¶39 col. 2:55-59
...wherein the sense strand is conjugated to at least one ligand which is one or more GalNAc derivatives... Inclisiran is alleged to be conjugated to an N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol ligand, a GalNAc derivative. ¶39 col. 4:41-44
  • '377 Patent Infringement Allegations
Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of inhibiting the expression of a...PCSK9 gene in a human subject... The proposed labeling for the accused product is alleged to instruct or encourage a method of inhibiting the expression of a PCSK9 gene. ¶61 col. 3:1-11
...comprising subcutaneously administering to the subject a fixed dose of 275 mg to 325 mg of a double stranded ribonucleic acid (RNAi) agent... The accused product is an injection containing 284 mg of inclisiran, a dose within the claimed range, and its labeling is alleged to instruct for subcutaneous administration of this fixed dose. ¶1; ¶61 col. 3:12-17
...wherein the double stranded RNAi agent comprises a sense strand... [with sequence of SEQ ID NO: 687] and the antisense strand... [with sequence of SEQ ID NO: 688]... The active ingredient, inclisiran, is alleged to comprise sense and antisense strands with nucleotide sequences identical to those recited in the claim. ¶63 claim 1
...and wherein the double stranded RNAi agent is conjugated to a N-acetylgalactosamine (GalNAc)3 ligand. The active ingredient, inclisiran, is alleged to be conjugated to a GalNAc3 ligand. ¶63 claim 1
  • Identified Points of Contention:
    • Validity vs. Infringement: The complaint alleges that in its notice letters, Cipla did not contest infringement of the asserted claims of either the '369 or '377 patent on any basis other than the alleged invalidity of those claims Compl. ¶40 Compl. ¶64 This suggests the central dispute in the case may concern the validity of the patents rather than a technical disagreement over whether the accused product meets the claim limitations.
    • Technical Mapping: The complaint's allegations for both patents map the features of the accused inclisiran product (composition, dosage, and method of use) directly onto the elements of the asserted independent claims. This direct mapping, combined with the alleged non-contestation of infringement, suggests the possibility that the infringement analysis may be less contentious than the validity analysis.

V. Key Claim Terms for Construction

  • Term ('369 Patent, Claim 1): "RNAi agent"

    • Context and Importance: Practitioners may focus on this term because its definition is fundamental to the scope of the composition claim. While the accused product is an RNAi agent, the precise boundaries of this term, particularly in light of the numerous chemical modifications described, could be a focal point in a validity challenge.
    • Intrinsic Evidence for a Broader Interpretation: The specification provides a broad functional definition, stating that the term refers to an agent that "mediates the targeted cleavage of an RNA transcript via an RNA-induced silencing complex (RISC) pathway" '369 Patent, col. 13:58-62
    • Intrinsic Evidence for a Narrower Interpretation: The specification also provides significant detail on specific structures, such as double-stranded agents of particular lengths and with specific modification patterns '369 Patent, col. 19:32-56, which a party could argue implicitly limits the scope of the term to the embodiments disclosed.

  • Term ('377 Patent, Claim 1): "fixed dose"

    • Context and Importance: This term is the central feature of the asserted method claim, distinguishing the invention from, for example, weight-based dosing regimens. The construction of "fixed dose" is critical to defining the scope of the patented method.
    • Intrinsic Evidence for a Broader Interpretation: The plain language of the claim, "a fixed dose of 275 mg to 325 mg," suggests a pre-determined quantity of the drug substance administered to a subject, irrespective of individual characteristics like body weight.
    • Intrinsic Evidence for a Narrower Interpretation: The specification discusses the benefits of a "fixed dose" of about 300 mg '377 Patent, col. 3:1-17, and the examples focus on specific dose amounts. A party might argue that the term should be understood in the specific context of the disclosed embodiments, although the claim itself provides an explicit numerical range.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Cipla will actively induce infringement of the patents-in-suit. This allegation is based on the assertion that the proposed product labeling for Cipla's ANDA Product will instruct, encourage, or promote the performance of the claimed methods Compl. ¶42 Compl. ¶61 Compl. ¶66 The complaint also alleges contributory infringement on the basis that the accused product is not a staple article of commerce and is not suitable for substantial noninfringing use Compl. ¶43 Compl. ¶67
  • Willful Infringement: The complaint does not contain an explicit count for willful infringement. However, it alleges that Cipla has knowledge of the patents-in-suit, citing the notice letters sent by Cipla to the Plaintiffs Compl. ¶34-35 Compl. ¶57-58 It further alleges that Cipla's activities will be done with "specific intent to infringe" Compl. ¶42 Compl. ¶66, which are factual predicates that could potentially support a future claim for willfulness.

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue will be one of patent validity: given that the complaint alleges infringement was not contested on technical grounds, the case will likely focus on whether Defendants can prove by clear and convincing evidence that the asserted claims are invalid, potentially based on prior art or other challenges in the crowded field of RNAi therapeutics.
  • A key question for the '377 patent is one of protected scope: does the patent's claiming of a method of administration using a "fixed dose" of 275 mg to 325 mg create a valid and enforceable patent right over the use of Cipla's 284 mg product, or is this dosage regimen rendered obvious or anticipated by prior art?
  • An underlying procedural question will be the impact of parallel litigation: how will the pre-existing litigation between the same parties over the same patents (C.A. 26-272-GBW) influence the proceedings, claim construction, and potential legal arguments in this new action?
Loading Complaint